Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar Monotherapy in Type 2 Diabetes
NCT02121717Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Jun 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of chiglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Akeso, Inc. Primary endpoint: Change in HbA1c from baseline at 24 weeks. Started Jun 2014; status: completed.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02121717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121717.